PlainRecalls
FDA Drug Moderate Class II Ongoing

HADLIMA (adalimumab-bwwd) injection, 40mg/0.8 mL, 2 Single-dose Prefilled Syringes per carton, Rx only, Manufactured for: Organon LLC, a subsidiary of ORGANON & Co, Jersey City, NJ 07302, Manufactured by: SAMSUN BIOEPIS Co., Ltd, Incheon, Republic of Korea, NDC 78206-183-01.

Reported: November 5, 2025 Initiated: October 10, 2025 #D-0099-2026

Product Description

HADLIMA (adalimumab-bwwd) injection, 40mg/0.8 mL, 2 Single-dose Prefilled Syringes per carton, Rx only, Manufactured for: Organon LLC, a subsidiary of ORGANON & Co, Jersey City, NJ 07302, Manufactured by: SAMSUN BIOEPIS Co., Ltd, Incheon, Republic of Korea, NDC 78206-183-01.

Reason for Recall

Lack of Assurance of Sterility.

Details

Recalling Firm
Samsung Bioepis Co., Ltd.
Units Affected
5,518 packs (11,036 Syringes) 2 syringes/carton)
Distribution
Distributed only to one warehouse in NJ. with no further distribution
Location
Yeonsu, N/A

Frequently Asked Questions

What product was recalled?
HADLIMA (adalimumab-bwwd) injection, 40mg/0.8 mL, 2 Single-dose Prefilled Syringes per carton, Rx only, Manufactured for: Organon LLC, a subsidiary of ORGANON & Co, Jersey City, NJ 07302, Manufactured by: SAMSUN BIOEPIS Co., Ltd, Incheon, Republic of Korea, NDC 78206-183-01.. Recalled by Samsung Bioepis Co., Ltd.. Units affected: 5,518 packs (11,036 Syringes) 2 syringes/carton).
Why was this product recalled?
Lack of Assurance of Sterility.
Which agency issued this recall?
This recall was issued by the FDA Drug on November 5, 2025. Severity: Moderate. Recall number: D-0099-2026.